Hematopoietic Stem Cell Transplantation

Mechanism

Related News

FDA Announces Reforms to Cell and Gene Therapy Manufacturing Requirements

Mar 12, 2026

The FDA issued reforms on January 11, 2026, loosening chemistry, manufacturing, and control requirements for cell and gene therapy products to advance innovation and accommodate the unique complexity of these treatments.

CAR T-cell therapy trial for progressive MS now recruiting; stem cell transplant trials advance

Mar 06, 2026

A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.